← All trials
NCT05415137
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2022
- Primary completion
- Dec 15, 2024
- Completion date
- Jan 15, 2025
- First posted
- Jun 10, 2022
- Last posted
- Dec 5, 2022
- Enrollment
- 264
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- aTyr PharmaLead sponsor
- Kyorin PharmaCollaborator
- aTyr PharmaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.